TY - JOUR
T1 - Heat Shock Protein 70 (HSP70) Induction
T2 - Chaperonotherapy for Neuroprotection after Brain Injury
AU - Kim, Jong Youl
AU - Barua, Sumit
AU - Huang, Mei Ying
AU - Park, Joohyun
AU - Yenari, Midori A.
AU - Lee, Jong Eun
PY - 2020/9/2
Y1 - 2020/9/2
N2 - The 70 kDa heat shock protein (HSP70) is a stress-inducible protein that has been shown to protect the brain from various nervous system injuries. It allows cells to withstand potentially lethal insults through its chaperone functions. Its chaperone properties can assist in protein folding and prevent protein aggregation following several of these insults. Although its neuroprotective properties have been largely attributed to its chaperone functions, HSP70 may interact directly with proteins involved in cell death and inflammatory pathways following injury. Through the use of mutant animal models, gene transfer, or heat stress, a number of studies have now reported positive outcomes of HSP70 induction. However, these approaches are not practical for clinical translation. Thus, pharmaceutical compounds that can induce HSP70, mostly by inhibiting HSP90, have been investigated as potential therapies to mitigate neurological disease and lead to neuroprotection. This review summarizes the neuroprotective mechanisms of HSP70 and discusses potential ways in which this endogenous therapeutic molecule could be practically induced by pharmacological means to ultimately improve neurological outcomes in acute neurological disease.
AB - The 70 kDa heat shock protein (HSP70) is a stress-inducible protein that has been shown to protect the brain from various nervous system injuries. It allows cells to withstand potentially lethal insults through its chaperone functions. Its chaperone properties can assist in protein folding and prevent protein aggregation following several of these insults. Although its neuroprotective properties have been largely attributed to its chaperone functions, HSP70 may interact directly with proteins involved in cell death and inflammatory pathways following injury. Through the use of mutant animal models, gene transfer, or heat stress, a number of studies have now reported positive outcomes of HSP70 induction. However, these approaches are not practical for clinical translation. Thus, pharmaceutical compounds that can induce HSP70, mostly by inhibiting HSP90, have been investigated as potential therapies to mitigate neurological disease and lead to neuroprotection. This review summarizes the neuroprotective mechanisms of HSP70 and discusses potential ways in which this endogenous therapeutic molecule could be practically induced by pharmacological means to ultimately improve neurological outcomes in acute neurological disease.
UR - http://www.scopus.com/inward/record.url?scp=85090508464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090508464&partnerID=8YFLogxK
U2 - 10.3390/cells9092020
DO - 10.3390/cells9092020
M3 - Review article
C2 - 32887360
AN - SCOPUS:85090508464
SN - 2073-4409
VL - 9
JO - Cells
JF - Cells
IS - 9
ER -